From the Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pa (H.C.O., H.S.K.); Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 330 Cedar St, TE 2-224, New Haven, CT 06510 (M.X., H.S.K.); and Yale Cancer Center, New Haven, Conn (H.S.K.).
Radiology. 2017 Mar;282(3):869-879. doi: 10.1148/radiol.2016160288. Epub 2016 Sep 27.
Purpose To evaluate the influence of bridging local-regional therapy (LRT) on hepatocellular carcinoma (HCC) recurrence and overall survival after orthotopic liver transplantation and to identify factors that predict HCC recurrence after orthotopic liver transplantation. Materials and Methods The United Network for Organ Sharing database was used to identify patients with HCC who underwent liver transplantation between 2002 and 2013. Patients with complete explant data within the Milan criteria for whom a Model for End-Stage Liver Disease exception was approved were retrospectively analyzed. Kaplan-Meier estimation was used for survival analysis with log-rank test and Cox proportional hazard models to assess independent prognostic factors for overall survival. Propensity-matched analysis for treatment groups was performed to minimize selection bias. Results The rate of tumor recurrence after liver transplantation was 11.5% (321 of 2794), which significantly decreased overall survival (P < .001). The bridging LRT group exhibited lower recurrence (59 of 686 [8.6%]; P = .02) and longer median overall survival (75.9 months; P < .001). Recurrence was higher in patients older than 60 years, serum α-fetoprotein greater than 400 mg/L, bilobar distribution, multiple lesions, absent necrosis, microvascular invasion, and tumors beyond the Milan criteria (P < .05). Age, LRT status, serum α-fetoprotein, and microvascular invasion were independent risk factors (P < .05). In the matched cohort, similar factors that predicted recurrence were observed (P < .05), whereas bridging LRT (P = .03) and serum α-fetoprotein (P = .02) were independent risk factors for recurrence. Conclusion LRT significantly decreased tumor recurrence and lengthened overall survival. RSNA, 2016.
评估桥接局部-区域治疗(LRT)对原位肝移植后肝细胞癌(HCC)复发和总生存的影响,并确定预测原位肝移植后 HCC 复发的因素。
利用美国器官共享联合网络数据库,选取 2002 年至 2013 年期间接受肝移植的 HCC 患者。对符合米兰标准且获得终末期肝病模型评分例外的患者进行回顾性分析,对完整的切除标本数据进行分析。采用 Kaplan-Meier 法进行生存分析,用对数秩检验和 Cox 比例风险模型评估总生存的独立预后因素。对治疗组进行倾向性匹配分析,以尽量减少选择偏倚。
肝移植后 HCC 复发率为 11.5%(2794 例中有 321 例),明显降低了总生存率(P<.001)。桥接 LRT 组复发率较低(686 例中有 59 例[8.6%];P=.02),中位总生存时间较长(75.9 个月;P<.001)。年龄>60 岁、血清甲胎蛋白>400 mg/L、双叶分布、多发病灶、无坏死、微血管侵犯和肿瘤超出米兰标准的患者复发率较高(P<.05)。年龄、LRT 状态、血清甲胎蛋白和微血管侵犯是独立的危险因素(P<.05)。在匹配队列中,也观察到了类似的预测复发的因素(P<.05),而桥接 LRT(P=.03)和血清甲胎蛋白(P=.02)是复发的独立危险因素。
LRT 可显著降低肿瘤复发率,延长总生存率。
RSNA,2016。